Search

everythinglearnresearchcommunity

for

Search:↓

There might be a link between male pattern baldness and a higher risk of prostate cancer and testicular cancer.

Hair loss can be an early sign of prostate enlargement.

Stopping finasteride improves sperm quality but not semen volume in young men.

Finasteride significantly reduces fertility in male rats.

D-004 may be a natural alternative to finasteride for treating enlarged prostate and male baldness.

Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.

Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.

Gender-affirming hormone treatments need better patient-focused outcome measurements and standardized data collection.

Testing for CAG repeat polymorphism in the androgen receptor gene is not currently recommended for managing hypogonadism.

A new compound was made that might help treat diseases related to male hormones.

Early balding, especially frontal, increases prostate cancer risk; more research needed.

Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.

Men with benign prostatic hyperplasia are more likely to have metabolic syndrome than those without it.

5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.

Dosing time affects finasteride's effectiveness and safety in rats.

Low androgen levels might delay prostate cancer but could lead to more aggressive, therapy-resistant cancers.

Finasteride reduces prostate size and PSA levels in young patients.

Testosterone increases muscle mass regardless of DHT conversion blocking.

Early hair loss may indicate prostate issues.

NcoA4 may have roles beyond helping control gene activity, possibly affecting cell behavior and stability.

Pueraria mirifica extract may help treat benign prostatic hyperplasia.

The document suggests more research is needed to understand the link between baldness and prostate cancer.

Male pattern baldness may predict prostate cancer risk.

Patients with metabolic syndrome had lower Gleason scores when diagnosed with prostate cancer.

Men with early balding may have a higher risk of prostate issues, and surgery for prostate cancer has a slight survival benefit over radiation.

ERG increases SOX9, promoting prostate cancer growth and invasion.

There's no link between hair loss type androgenic alopecia and benign prostatic hyperplasia, but early hair loss and family history can mean more severe alopecia.

Urinary PSA could be an early marker for enlarged prostate.

Alopecia should be treated as a medical condition because it may increase the risk of serious diseases and psychological issues.

Men who start losing hair at 20 may have a higher chance of getting prostate cancer later.